SAVENE Powder and solvent for solution for infusion (2019)
Βιβλιογραφική αναφορά
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Περιεχόμενα
Name of the medicinal product
Savene 20 mg/ml powder and solvent for concentrate for solution for infusion.
Qualitative and quantitative composition
Each vial contains 500 mg dexrazoxane (589 mg dexrazoxane hydrochloride). Each ml contains 20 mg of dexrazoxane after reconstitution with 25 ml of Savene solvent. Excipients with known effects: Solvent ...
Pharmaceutical form
Powder and solvent for concentrate for solution for infusion. Powder vial: White to off-white lyophilisate. Solvent bottle: Clear isotonic solution (295 mOsml/l, pH approx. 7.4).
Therapeutic indications
Savene is indicated in adults for the treatment of anthracycline extravasation.
Posology and method of administration
Savene must be administered under the supervision of a physician experienced in the use of anti-cancer medicinal products. Posology Treatment should be given once daily for 3 consecutive days. The recommended ...
Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Women of childbearing potential not using contraceptive measures (see section 4.6). Breast-feeding (see section ...
Special warnings and precautions for use
Continuous monitoring Local examination should be performed on a regular basis after treatment until resolution. If there is suspicion of extravasation by vesicant compounds other than anthracyclines through ...
Interaction with other medicinal products and other forms of interaction
Concomitant use contraindicated: Yellow fever vaccine: Risk of fatal generalised vaccinial disease (see section 4.3). Concomitant use not recommended: Other live attenuated vaccines: risk of systemic, ...
Pregnancy and lactation
Women of childbearing potential/Contraception in males and females Since dexrazoxane possesses mutagenic activity and is used with anthracyclines known to have cytotoxic, mutagenic and embryotoxic properties, ...
Effects on ability to drive and use machines
Dizziness, somnolence and syncope have been reported in a few patients included in Savene studies TT01 and TT02 (see section 4.8). Dexrazoxane has minor influence on the ability to drive and use machines. ...
Undesirable effects
A number of published reports comprising more than 1000 patients have demonstrated a uniform pattern of dose dependent adverse reactions. Most common adverse reactions are nausea/vomiting, bone marrow ...
Overdose
Signs and symptoms of overdosage are likely to consist of leucopenia, thrombocytopenia, nausea, vomiting, diarrhoea, skin reactions and alopecia. Treatment should be symptomatic.
Pharmacodynamic properties
Pharmacotherapeutic group: Detoxifying agents for antineoplastic agents ATC code: V03AF02 Two pharmacodynamic properties of dexrazoxane are described in the literature: Prevention of anthracycline cardiotoxicity, ...
Pharmacokinetic properties
Savene must only be administered intravenously. Distribution Bibliographical data demonstrate that serum kinetics of dexrazoxane after intravenous administration follow an open two-compartment model independent ...
Preclinical safety data
Repeat-dose toxicity studies with dexrazoxane have shown that primary target organs were tissues that undergo rapid cell division: bone marrow, lymphoid tissue, testes and digestive tract. Myelosuppression ...
List of excipients
Powder vial: none Solvent bottle: Sodium chloride Potassium chloride Magnesium chloride hexahydrate Sodium acetate trihydrate Sodium gluconate Sodium hydroxide Water for injections
Incompatibilities
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.
Shelf life
Shelf life Powder and solvent: 3 years. After reconstitution and dilution: Chemical and physical in-use stability has been demonstrated for 4 hours when stored at 2 to 8°C. From a microbiological point ...
Special precautions for storage
Store below 25°C. Keep the vials and bottles in the outer carton in order to protect from light. For storage conditions after reconstitution and dilution of the medicinal product, see section 6.3.
Nature and contents of container
Savene powder: Amber-coloured, 36-ml, glass type I vial with stopper made of chlorobutyl rubber and a flip-off cap. Savene solvent: 500 ml solution in bottles made of Type-I (Ph.Eur.) glass. Pack sizes: ...
Special precautions for disposal and other handling
Before infusion, Savene powder must be reconstituted with 25 ml Savene solvent to give a concentration of 20 mg dexrazoxane per ml. The concentrate is slightly yellow. The concentrate should then be diluted ...
Marketing authorization holder
Clinigen Healthcare B.V., Schiphol Boulevard 359, WTC Schiphol Airport, D Tower 11th floor, 1118BJ, Schiphol, The Netherlands
Marketing authorization number(s)
EU/1/06/350/001
Date of first authorization / renewal of the authorization
Date of first authorisation: 28 July 2006 Date of latest renewal: 18 July 2011
Πηγαίο έγγραφο
Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση: